Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016.  

He will help Revance progress toward regulatory approval and commercialization of RT002 injectable, a novel neurotoxin product candidate, and further expand the company's pipeline into a variety of therapeutic areas. 

Concurrent with Mr. Gangolli's appointment, James Glasheen, Ph.D., will step down from the Revance Board of Directors.

In his current role at GW Pharmaceuticals, Mr. Gangolli is spearheading the buildout of the company's U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for diverse indications.

Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products. Prior to Allergan, he served as Vice President, Sales and  Marketing at VIVUS, Inc. Before VIVUS, Mr. Gangolli served in a number of senior marketing roles at Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the UK. He received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England.